Aňa Lluch

Research interests

Publications

• Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

  npj Breast Cancer · 2021 · 10.1038/s41523-020-00208-2

• Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

  Cancer Research · 2017 · 10.1158/0008-5472.can-16-2717

• MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

  Cell Metabolism · 2017 · 10.1016/j.cmet.2017.09.009

• 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)00163-7

• Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv395

• Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

  Annals of Oncology · 2015 · 10.1093/annonc/mdv161

• Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70080-4

• Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

  Annals of Oncology · 2012 · 10.1093/annonc/mds132

• Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.37.4207

• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

  The Lancet Oncology · 2011 · https://doi.org/10.1016/s1470-2045(11)70336-9

• PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer

  Molecular Cancer Therapeutics · 2011 · 10.1158/1535-7163.mct-10-1089

• Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways

  Cancer Treatment Reviews · 2011 · 10.1016/j.ctrv.2011.11.005

• Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer

  Clinical Cancer Research · 2010 · 10.1158/1078-0432.ccr-10-1265

• Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

  The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(09)61964-4

• Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer

  Clinical Cancer Research · 2010 · 10.1158/1078-0432.ccr-10-1265

• Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research

  Cancer Treatment Reviews · 2010 · 10.1016/j.ctrv.2009.12.002

• Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

  Breast Cancer Research · 2010 · 10.1186/bcr2594

• Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa0910320

• Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

  Cancer Research · 2009 · https://doi.org/10.1158/0008-5472.can-08-3441

• Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.19.2567

• AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

  Cancer Cell · 2009 · 10.1016/j.ccr.2009.04.012

• AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

  Cancer Cell · 2009 · 10.1016/j.ccr.2009.04.012

• Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

  JNCI Journal of the National Cancer Institute · 2008 · 10.1093/jnci/djn151

• An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

  Cancer Research · 2008 · https://doi.org/10.1158/0008-5472.can-07-6854

• Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2006.08.9102

• p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer

  Clinical Cancer Research · 2006 · 10.1158/1078-0432.ccr-05-1807

• p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer

  Clinical Cancer Research · 2006 · 10.1158/1078-0432.ccr-05-1807

• Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.04.173

• Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.04.173

• Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.08.326

• NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.

  PubMed · 2002

Current projects

No projects listed.